Virax Biolabs Introduces RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit

Kits available in November for Distribution

Virax Biolabs ("Virax" or the "Company") (Nasdaq: VRAX), an innovative biotechnology company focused on the prevention, detection, and diagnosis of viral diseases, announced today the distribution of a RSV-Influenza-COVID Triple Virus Antigen Rapid Test Kit has been launched in markets accepting the CE mark, such as the European Union. The test kits are for use in both at-home and in point-of-care settings to accurately identify infections related to respiratory syncytial virus (RSV), influenza and COVID-19 with results typically available in 15 minutes. The specialized diagnostic kits can be found by contacting the company's sales representatives.

While lesser known to the general public than influenza and COVID-19, RSV can be a serious illness.  According to the European Health Management Association, RSV is the most common cause of hospitalization in infants and also causes a large number of hospitalizations among the elderly.  RSV infection can lead to pneumonia, congestive heart failure and severe symptoms in those with preexisting conditions involving the lungs.

https://finance.yahoo.com/news/virax-biolabs-introduces-rsv-influenza-113000992.html